Product launches forecast to propel systemic sclerosis market to $1.8 billion by 2030

21 June 2021

The data and analytics company GlobalData has predicted that the value of the systemic sclerosis (SSc) market will grow from $498 million in 2020 to $1.8 billion in 2030 across the seven major markets (7MM) at a compound annual growth rate (CAGR) of 14%.

GlobalData’s report, Systemic Sclerosis: Global Drug Forecast and Market Analysis to 2030, reveals that recent and anticipated product launches will create new treatment options for SSc patients, leading to unprecedented market growth.

The report focuses on the treatment landscape for SSc-associated skin fibrosis, lung fibrosis, and digital vasculopathy.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK